MarketCap
Facebook
X
Telegram
Catalyst Pharmaceuticals Income Statement 2025-2002 | CPRX
Brief overview of profit and loss at Catalyst Pharmaceuticals
The figures are compared over a five-year interval. According to figures from Catalyst Pharmaceuticals, revenue changed from 119 million dollars to 589 million dollars over five years. The cumulative result was +394.6%, corresponding to roughly 37.7% per year. The company expanded its revenue base at a high speed.
The five-year change in gross profit reached +391.7%: from 102 million dollars to 502 million dollars. The cost base moved against the top-line trend and weighed on the gross result. Gross margin moved from 85.7% to 85.2%. The relationship between gross profit and revenue changed only slightly.
The five-year EBITDA result moved by +523.6%: from 41.4 million dollars to 258 million dollars. Operating profitability strengthened faster than the scale of sales. EBITDA margin moved from 34.8% to 43.8%. Higher profitability strengthens the quality of operating growth.
Net income changed from $75 million to $214 million (+185.8%). The period finished with its strongest net-income result.
The market value of the business moved from 377 million dollars to 3 billion dollars, or +706.9%. Capitalization moved ahead of the business fundamentals.
Conclusion
The five-year financial profile is predominantly positive. Key strengths include consistent sales economics, a larger revenue base and net-income growth. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Catalyst Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
3.04 B | 2.44 B | 1.56 B | 1.48 B | 595 M | 377 M | 431 M | 254 M | 299 M | 90.3 M | 150 M | 234 M | 90.5 M | 16.2 M | 23.7 M | 18.8 M | - | - | - | - | - | - | - | - |
Shares |
122 M | 118 M | 106 M | 103 M | 103 M | 104 M | 103 M | 103 M | 85.8 M | 82.9 M | 80.9 M | 64.1 M | 45.5 M | 30 M | 21.7 M | 18.6 M | - | - | - | - | - | - | - | - |
Historical Prices |
24.9 | 20.6 | 14.7 | 14.3 | 5.76 | 3.64 | 4.11 | 2.52 | 3.39 | 1.12 | 1.86 | 3.65 | 1.95 | 0.52 | 1.08 | 1.01 | 0.87 | 3.42 | 4.3 | - | - | - | - | - |
Net Income |
214 M | 164 M | 71.4 M | 83.1 M | 39.5 M | 75 M | 31.9 M | -34 M | -18.4 M | -18.1 M | -20.2 M | -15.5 M | -12.2 M | -4.08 M | -6.39 M | -4.01 M | -7.24 M | -10.6 M | -4.14 M | -2.73 M | -1.81 M | -540 K | -429 K | -256 K |
Revenue |
589 M | 492 M | 398 M | 214 M | 141 M | 119 M | 102 M | 500 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
87.3 M | 68.8 M | 52 M | 34.4 M | 21.9 M | 17 M | 14.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 87.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
258 M | 195 M | 86.8 M | 102 M | 52.4 M | 41.3 M | 31.8 M | -35.3 M | -18.7 M | -19.3 M | -20.4 M | -14.6 M | -10.3 M | -5.22 M | -6.08 M | -4.02 M | -7.28 M | - | - | - | - | - | - | - |
Interest Expense |
25.7 M | 21.1 M | 7.7 M | 2.88 M | 282 K | 587 K | 1.59 M | 1.29 M | 454 K | 322 K | 100 K | 76.2 K | 47.4 K | 15 K | - | - | - | - | - | - | - | - | - | - |
EBITDA |
258 M | 196 M | 87.1 M | 102 M | 52.6 M | 41.4 M | 32.1 M | -35.3 M | -18.6 M | -19.2 M | -20.4 M | -14.6 M | -10.3 M | -5.21 M | -6.04 M | -4 M | -7.25 M | - | - | - | - | - | - | - |
Operating Expenses |
206 M | 190 M | 227 M | 76.9 M | - | - | 55.7 M | 35.8 M | 18.7 M | 19.3 M | 20.4 M | 14.6 M | 10.3 M | 5.22 M | 6.08 M | 4.51 M | 7.28 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
63.1 M | 59 M | 42.2 M | 26 M | 49.6 M | 44.2 M | 36.9 M | 15.9 M | 7.3 M | 7.91 M | 8.6 M | 4.47 M | 2.21 M | 2.56 M | 2.7 M | 2.21 M | 2.18 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Catalyst Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
122 M | 123 M | 122 M | 121 M | 121 M | 119 M | 118 M | 117 M | 107 M | 107 M | 106 M | 106 M | 105 M | 103 M | 103 M | 103 M | 103 M | 103 M | 103 M | 104 M | 104 M | 104 M | 103 M | 103 M | 103 M | 103 M | 103 M | 103 M | 103 M | 103 M | 103 M | 103 M | 103 M | 84.8 M | 83.9 M | 83 M | 83 M | 82.9 M | 82.9 M | 82.9 M | 82.9 M | 82.5 M | 82 M | 76 M | 69.1 M | 67.2 M | 66.2 M | 54.1 M | 54.1 M | 44.7 M | 41.4 M | 41.4 M | 41.4 M | 32.1 M | 26.9 M | 24.7 M | 24.7 M | 21.7 M | 21.7 M | 24.7 M |
Net Income |
63.7 M | 52.8 M | 52.1 M | 56.7 M | - | 43.9 M | 40.8 M | 23.3 M | - | -30.8 M | 37.8 M | 29.6 M | - | 22.7 M | 21.6 M | 13.2 M | - | 10.3 M | 12.2 M | 7.66 M | - | 43.3 M | 9.78 M | 10.4 M | 7.93 M | 13.6 M | 11 M | -645 K | -14.5 M | -7.84 M | -5.97 M | -5.7 M | -5.39 M | -4.18 M | -3.88 M | -4.97 M | -4.16 M | -3.95 M | -4.57 M | -5.39 M | -5.82 M | -4.45 M | -4.56 M | -5.41 M | -3.49 M | -5.01 M | -3.2 M | -3.81 M | -1.35 M | -5.91 M | -3.14 M | -1.74 M | -76.6 K | -2.62 M | -289 K | -1.09 M | -2.35 M | -1.13 M | -1.39 M | -1.52 M |
Revenue |
149 M | 148 M | 147 M | 141 M | - | 129 M | 123 M | 98.5 M | - | 103 M | 99.6 M | 85.4 M | - | 57.2 M | 53.1 M | 43.1 M | - | 36 M | 36.4 M | 30.2 M | - | 29.3 M | 29.6 M | 29.1 M | 30.1 M | 30.9 M | 28.8 M | 12.4 M | 500 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
14.5 M | 22.7 M | 20.6 M | 17.9 M | - | 19.3 M | 15.4 M | 12.5 M | - | 14.2 M | 12 M | 9.95 M | - | 9.66 M | 7.64 M | 5.89 M | - | 5.31 M | 4.54 M | 4.68 M | - | 3.88 M | 4.14 M | 4.15 M | - | 4.39 M | 4.26 M | 1.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
73.2 M | 66.3 M | 66.3 M | 63.4 M | - | 50.9 M | 54.2 M | 27.1 M | - | -37.2 M | 46.7 M | 35.6 M | - | 25.1 M | 28.6 M | 17.4 M | - | 14 M | 15.8 M | 9.8 M | - | 11.7 M | 10.3 M | 10.7 M | 8.01 M | 13.8 M | 11 M | -988 K | -14.8 M | -8.18 M | -6.34 M | -5.93 M | -5.51 M | -4.31 M | -4.18 M | -4.68 M | -4.31 M | -3.91 M | -4.81 M | -6.24 M | -6.19 M | -5.02 M | -4.9 M | -4.29 M | -3.98 M | -4.11 M | -2.99 M | -3.51 M | -2.71 M | -3.25 M | -2.65 M | -1.71 M | -1.51 M | -1.28 M | -1.07 M | -1.36 M | -2.03 M | -1.13 M | -1.4 M | -1.52 M |
Interest Expense |
11 M | 4.77 M | 3 M | 7.92 M | - | 6.3 M | 1.54 M | 1.96 M | - | -833 K | 1.81 M | 1.7 M | - | 905 K | -324 K | 93 K | - | 68 K | 62 K | 81 K | - | 33 K | 111 K | 336 K | - | 393 K | 450 K | 343 K | - | 344 K | 371 K | 234 K | - | 129 K | 91 K | 110 K | - | 67 K | 92.8 K | 118 K | - | 46.7 K | 4.87 K | 61.9 K | - | 5.92 K | 15.7 K | 32.8 K | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
73.3 M | - | - | 63.5 M | - | - | - | 27.2 M | - | - | - | 35.7 M | - | 25.2 M | 28.6 M | 17.4 M | - | 14.2 M | 16 M | 9.9 M | - | 11.8 M | 10.3 M | 10.7 M | 8.01 M | 13.9 M | 11 M | -974 K | -14.8 M | -8.17 M | -6.33 M | -5.93 M | -5.51 M | -4.29 M | -4.17 M | -4.67 M | -4.31 M | -3.9 M | -4.81 M | -6.22 M | -6.19 M | -5.01 M | -4.89 M | -4.28 M | -3.98 M | -4.1 M | -2.98 M | -3.5 M | -2.71 M | -3.24 M | -2.65 M | -1.7 M | -1.51 M | -1.28 M | -1.06 M | -1.36 M | -2.03 M | -1.12 M | -1.38 M | -1.51 M |
Operating Expenses |
52 M | 50.1 M | 50.3 M | 50.8 M | - | 49.2 M | 43.7 M | 49.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.9 M | 13.4 M | - | 8.18 M | 6.34 M | 5.93 M | - | 4.31 M | 4.18 M | 4.68 M | - | 3.91 M | 4.81 M | 6.24 M | - | 5.02 M | 4.9 M | 4.29 M | - | 4.11 M | 2.99 M | 3.51 M | - | 3.25 M | 2.65 M | 1.71 M | - | 1.28 M | 1.07 M | 1.36 M | - | 1.13 M | 1.4 M | 1.52 M |
General and Administrative Expenses |
17.8 M | 15 M | 14.8 M | 14.8 M | - | 14.9 M | 12.6 M | 19.9 M | - | 33.6 M | 28.4 M | 29.7 M | - | 13.6 M | 12.9 M | 16.4 M | - | 12.2 M | 11.5 M | 12.7 M | - | 9.98 M | 10.8 M | 10.1 M | - | 8.07 M | 8.99 M | 8.42 M | - | 3.64 M | 2.63 M | 2.67 M | - | 1.6 M | 1.73 M | 1.87 M | - | 1.42 M | 2.31 M | 2.69 M | - | 1.97 M | 2.32 M | 1.94 M | - | 1.22 M | 891 K | 760 K | - | 441 K | 521 K | 613 K | - | 629 K | 535 K | 637 K | - | 517 K | 492 K | 615 K |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Catalyst Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
